摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(2-aminoethyl)thymidine | 34387-59-2

中文名称
——
中文别名
——
英文名称
3-(2-aminoethyl)thymidine
英文别名
3-(2-Aminoethyl)thymidin;3-(2-aminoethyl)-1-((2R,4S,5R)-tetrahydro-4-hydroxy-5-(hydroxymethyl)furan-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;3-(2-aminoethyl)-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
3-(2-aminoethyl)thymidine化学式
CAS
34387-59-2
化学式
C12H19N3O5
mdl
——
分子量
285.3
InChiKey
CGVYPTXNHYHAQM-IVZWLZJFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    513.1±60.0 °C(Predicted)
  • 密度:
    1.404±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -1.9
  • 重原子数:
    20
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    116
  • 氢给体数:
    3
  • 氢受体数:
    6

SDS

SDS:dc322d44352fb7e33435e9b3223d8d1d
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6-(bis(pyridin-2-ylmethyl)amino)hexanoic acid3-(2-aminoethyl)thymidine1-羟基苯并三唑盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺三乙胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 以47%的产率得到6-(bis((pyridin-2-yl)methyl)amino)-N-(2-(2,3-dihydro-3-((2R,4S,5R)-tetrahydro-4-hydroxy-5-(hydroxymethyl)furan-2-yl)-5-methyl-2,6-dioxopyrimidin-1(6H)-yl)ethyl)hexanamide
    参考文献:
    名称:
    Re(CO)3胸苷配合物的合成,细胞毒性和作用方式的见解。
    摘要:
    核苷类似物被广泛用于癌症和病毒性疾病的治疗。迄今为止,几乎没有研究过有机or(I)配合物的抗增殖特性。在这里,我们介绍胸苷和尿苷的Re I(CO)3核心配合物的合成,表征和体外评估。用于绑定Re I(CO)3作为核心,在位置C5',C2',N3和C5处引入具有不同长度间隔基的三齿二聚二烯丙基胺金属螯合物。相应的有机金属胸苷配合物通过IR和NMR光谱法和质谱法充分表征。评估了它们对A549肺癌细胞系的细胞毒性。毒性取决于结合的部位和方式,以及系链的性质和长度。观察到用于承载铼部分在位置C5'或N3缀合物中等毒性(IC 50 = 124-160μ中号)。对于在C2'或C5处修饰的复合物,未观察到毒性。在C5'处带有十二碳烯间隔基的配合物53具有显着的毒性,并且比顺铂更有效,IC 50为50的6.0μ值中号。据我们所知,这是[M(CO)3 ] + 1-核苷结合物的抗增殖特性的首次报道。在使用A5
    DOI:
    10.1002/cmdc.201000196
  • 作为产物:
    描述:
    beta-胸苷钾硼氢potassium carbonate 作用下, 以 乙醇N,N-二甲基甲酰胺丙酮 为溶剂, 反应 10.0h, 生成 3-(2-aminoethyl)thymidine
    参考文献:
    名称:
    胸腺嘧啶激酶1-靶向的硼烷嘧啶核苷核苷类似物的合成及评估,用于硼中子俘获疗法的癌症
    摘要:
    合成了十六个第二代氨基和酰胺基取代的碳硼烷基嘧啶核苷类似物的文库,并设计为可用于癌症的硼中子捕获疗法(BNCT)的胸苷激酶1(TK1)的底物和抑制剂,并通过酶动力学进行了评估-,酶抑制-,代谢组学和生物分布研究。这些第二代碳硼烷基嘧啶核苷类似物(YB18A [ 3 ])中的一个,氨基直接与通过乙烯间隔基束缚在胸腺嘧啶3位上的间甲碳氢化合物笼相连,具有约3-4倍的底物hTK1和抑制剂比N5 - 2OH(2-),是第一代碳硼烷基嘧啶核苷类似物。既2和3似乎是5'-单磷酸化在TK1(+)细胞RG2,无论在体外和体内。对携带脑内RG2神经胶质瘤的大鼠进行生物分布研究后,选择性摄取了3种肿瘤,瘤内浓度大约是2种的4倍。获得的结果大大提高了对TK1和碳硼烷基嘧啶核苷类似物之间结合相互作用的理解,并将深刻影响这些试剂的未来设计策略。
    DOI:
    10.1016/j.ejmech.2015.05.042
点击查看最新优质反应信息

文献信息

  • Radiosynthesis and evaluation of novel 99mTc(CO)3-labelled thymidine dithiocarbamate derivatives for tumor imaging with SPECT
    作者:Xiaojiang Duan、Qing Ruan、Qianqian Gan、Xiaoqing Song、Si'an Fang、Xuran Zhang、Junbo Zhang
    DOI:10.1016/j.jorganchem.2018.05.009
    日期:2018.8
    A series of novel thymidine dithiocarbamate derivatives (DTC-TdR) were successfully synthesized and then radiolabelled using [Tc-99m(CO)(3)](+) core with high yields. The chemical characterizations of Tc-99m(CO)(3)-labelled dithiocarbamate derivatives have been carried out by preparing their corresponding rhenium complexes. The radiotracers were stable in vitro, and the partition co efficient results indicated that they were lipophilic. The cell uptake studies showed the uptakes of these(99m)Tc(CO)(3)-labelled thymidine derivatives were mediated by nucleoside transporters. Biodistribution of the complexes in mice bearing tumor showed that they had high tumor uptake and good tumor/muscle ratio. A clear SPECT imaging of the tumor location was obtained in mice bearing S180 tumor with one of radiotracers, suggesting they would be potential tumor imaging agents. (C) 2018 Elsevier B.V. All rights reserved.
  • Synthesis, In Vitro, and In Silico Evaluation of Organometallic Technetium and Rhenium Thymidine Complexes with Retained Substrate Activity toward Human Thymidine Kinase Type 1
    作者:Dominique Desbouis、Harriet Struthers、Vojtech Spiwok、Tatiana Küster、Roger Schibli
    DOI:10.1021/jm800530p
    日期:2008.11.13
    Human cytosolic thymidine kinase (hTK1) has proven to be a suitable target for noninvasive imaging of cancer cell proliferation using radiolabeled substrates such as [F-18]fluorothymidine ([F-18]FLT). However, a thymidine tracer useful for single photon emission tomography (SPECT) based off the inexpensive radionuclide technetium-99m would be of significant interest. In this work, a series of thymidine derivatives labeled with the organometallic [M(CO)(3)](+) core (M = Tc-99m, Re) were synthesized. Neutral, cationic, and anionic complexes were readily formed in aqueous media. and all were substrates of recombinant hTK1 when incubated with ATP. The neutral complexes were phosphorylated to a greater extent than the charged complexes. The extent of phosphorylation was further improved by increasing the spacer length separating thymidine and the organometallic core. A molecular dynamics Simulation Study performed with a modified hTK1 structure Supported the experimental findings. In vitro cell internalization experiments performed if) a human neuroblastoma cell line (SKNMC) showed low uptake of the charged complexes but significant uptake for the neutral, lipophilic complexes with a log P value > 1.
  • Synthesis, Cytotoxicity, and Insight into the Mode of Action of Re(CO)3 Thymidine Complexes
    作者:Mark D. Bartholomä、Anthony R. Vortherms、Shawn Hillier、Birgit Ploier、John Joyal、John Babich、Robert P. Doyle、Jon Zubieta
    DOI:10.1002/cmdc.201000196
    日期:2010.9.3
    and C5 with spacers of various lengths. The corresponding organometallic thymidine complexes were fully characterized by IR and NMR spectroscopy and mass spectrometry. Their cytotoxicity was assessed against the A549 lung carcinoma cell line. Toxicity is dependent on the site and mode of conjugation as well as on the nature and the length of the tether. Moderate toxicity was observed for conjugates carrying
    核苷类似物被广泛用于癌症和病毒性疾病的治疗。迄今为止,几乎没有研究过有机or(I)配合物的抗增殖特性。在这里,我们介绍胸苷和尿苷的Re I(CO)3核心配合物的合成,表征和体外评估。用于绑定Re I(CO)3作为核心,在位置C5',C2',N3和C5处引入具有不同长度间隔基的三齿二聚二烯丙基胺金属螯合物。相应的有机金属胸苷配合物通过IR和NMR光谱法和质谱法充分表征。评估了它们对A549肺癌细胞系的细胞毒性。毒性取决于结合的部位和方式,以及系链的性质和长度。观察到用于承载铼部分在位置C5'或N3缀合物中等毒性(IC 50 = 124-160μ中号)。对于在C2'或C5处修饰的复合物,未观察到毒性。在C5'处带有十二碳烯间隔基的配合物53具有显着的毒性,并且比顺铂更有效,IC 50为50的6.0μ值中号。据我们所知,这是[M(CO)3 ] + 1-核苷结合物的抗增殖特性的首次报道。在使用A5
  • Synthesis and evaluation of thymidine kinase 1-targeting carboranyl pyrimidine nucleoside analogs for boron neutron capture therapy of cancer
    作者:Hitesh K. Agarwal、Ahmed Khalil、Keisuke Ishita、Weilian Yang、Robin J. Nakkula、Lai-Chu Wu、Tehane Ali、Rohit Tiwari、Youngjoo Byun、Rolf F. Barth、Werner Tjarks
    DOI:10.1016/j.ejmech.2015.05.042
    日期:2015.7
    amido-substituted carboranyl pyrimidine nucleoside analogs, designed as substrates and inhibitors of thymidine kinase 1 (TK1) for potential use in boron neutron capture therapy (BNCT) of cancer, was synthesized and evaluated in enzyme kinetic-, enzyme inhibition-, metabolomic-, and biodistribution studies. One of these 2nd generation carboranyl pyrimidine nucleoside analogs (YB18A [3]), having an amino group directly
    合成了十六个第二代氨基和酰胺基取代的碳硼烷基嘧啶核苷类似物的文库,并设计为可用于癌症的硼中子捕获疗法(BNCT)的胸苷激酶1(TK1)的底物和抑制剂,并通过酶动力学进行了评估-,酶抑制-,代谢组学和生物分布研究。这些第二代碳硼烷基嘧啶核苷类似物(YB18A [ 3 ])中的一个,氨基直接与通过乙烯间隔基束缚在胸腺嘧啶3位上的间甲碳氢化合物笼相连,具有约3-4倍的底物hTK1和抑制剂比N5 - 2OH(2-),是第一代碳硼烷基嘧啶核苷类似物。既2和3似乎是5'-单磷酸化在TK1(+)细胞RG2,无论在体外和体内。对携带脑内RG2神经胶质瘤的大鼠进行生物分布研究后,选择性摄取了3种肿瘤,瘤内浓度大约是2种的4倍。获得的结果大大提高了对TK1和碳硼烷基嘧啶核苷类似物之间结合相互作用的理解,并将深刻影响这些试剂的未来设计策略。
查看更多